Research and Markets (http://www.researchandmarkets.com/research/h8bwdj/oral_therapies) has announced the addition of Decision Resources, Inc's new report "Oral Therapies for Type 2 Diabetes: Physician and Payer Perspectives on the Dynamics in the Chinese and South Korean Markets" to their offering.
China has the largest prevalent population of type 2 diabetes in the world and an ever-expanding affluent middle class, while South Korea has one of the most advanced healthcare systems in the world. The very low risk of hypoglycemia and excellent tolerability associated with DPP-IV inhibitors make this class suitable for widespread use for type 2 diabetes, but high-cost brands face unique market access challenges in each of these markets.
Surveyed physicians state that DPP-IV inhibitor prescribing is more common in South Korea than in China, however, by the end of 2013, the majority of physicians from both markets expect to increase their prescribing of DPP-IV inhibitors. Currently, two DPP-IV inhibitors have launched in South Korea: Merck's Januvia (sitagliptin) and Novartis's Galvus (vildagliptin).
In China, only Merck's Januvia is available, and even this brand does not yet appear on China's National Reimbursement Drug List. Bristol-Myers Squibb/AstraZeneca's Onglyza (saxagliptin) will launch in South Korea and China by the end of 2011. Two other DPP-IV inhibitors, Boehringer Ingelheim/Eli Lilly's Tradjenta (linagliptin) and Takeda/Furiex Pharmaceuticals' Nesina (alogliptin) will enter the South Korean and Chinese markets approximately two years after their expected debut in the Western markets.
Key Topics Covered:
Abbreviations Used in This Report Slides
Executive Summary Slides
Commercial Context Slides
Overview and Analysis of Reimbursement of Oral Antidiabetics in China and South
Analysis of Survey Results Slides
Healthcare Briefing - China and South Korea Slides
About the Author Slide
For Further Information Slide
For more information visit http://www.researchandmarkets.com/research/h8bwdj/oral_therapies
Source: Decision Resources, IncBusiness Wire
Last updated on: 03/10/2012